3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
3
Completed
3
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
17
Glioblastoma
8
Esophageal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Rectal Neoplasms
7
Oropharyngeal Neoplasms
7
Breast Neoplasms
7
Mouth Neoplasms
6
Glioma
6
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Laryngeal Neoplasms
4
Head and Neck Neoplasms
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Sarcoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Neuroblastoma
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Melanoma
2
Medulloblastoma
2
Hypopharyngeal Neoplasms
2
Ganglioneuroblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
venetoclax
124
Azacitidine
96
Cytarabine
71
fludarabine
44
Specimen Handling
38
Cyclophosphamide
38
Daunorubicin
27
Decitabine
26
Biopsy
25
Idarubicin
24
Granulocyte Colony-Stimulating Factor
21
gilteritinib
18
Injections
18
fludarabine phosphate
17
Whole-Body Irradiation
17
Melphalan
16
Busulfan
16
Stem Cell Transplantation
15
Mycophenolic Acid
15
ivosidenib
13
Cladribine
13
decitabine and cedazuridine drug combination
12
Gemtuzumab
12
Tacrolimus
11
CPX-351
11
X-Rays
10
Filgrastim
10
revumenib
9
enasidenib
9
Cyclosporine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myeloid, Acute
×
Radiation
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled